- Home
- YMAB vs BWAY Comparison
YMAB vs BWAY Comparison
Compare YMAB & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- BWAY
- Stock Information
- Founded
- YMAB 2015
- BWAY 2003
- Country
- YMAB United States
- BWAY Israel
- Employees
- YMAB N/A
- BWAY N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- YMAB Health Care
- BWAY Health Care
- Exchange
- YMAB Nasdaq
- BWAY Nasdaq
- Market Cap
- YMAB 218.4M
- BWAY 207.4M
- IPO Year
- YMAB 2018
- BWAY 2019
- Fundamental
- Price
- YMAB $3.89
- BWAY $8.76
- Analyst Decision
- YMAB Buy
- BWAY Strong Buy
- Analyst Count
- YMAB 11
- BWAY 3
- Target Price
- YMAB $18.73
- BWAY $13.17
- AVG Volume (30 Days)
- YMAB 216.5K
- BWAY 24.4K
- Earning Date
- YMAB 05-13-2025
- BWAY 05-13-2025
- Dividend Yield
- YMAB N/A
- BWAY N/A
- EPS Growth
- YMAB N/A
- BWAY N/A
- EPS
- YMAB N/A
- BWAY 0.06
- Revenue
- YMAB $87,685,000.00
- BWAY $41,016,000.00
- Revenue This Year
- YMAB N/A
- BWAY $351.53
- Revenue Next Year
- YMAB $18.83
- BWAY $21.84
- P/E Ratio
- YMAB N/A
- BWAY $57.37
- Revenue Growth
- YMAB 3.38
- BWAY 29.04
- 52 Week Low
- YMAB $3.84
- BWAY $5.13
- 52 Week High
- YMAB $17.47
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- YMAB 40.44
- BWAY 47.80
- Support Level
- YMAB $3.76
- BWAY $8.61
- Resistance Level
- YMAB $4.60
- BWAY $9.09
- Average True Range (ATR)
- YMAB 0.33
- BWAY 0.38
- MACD
- YMAB -0.02
- BWAY 0.05
- Stochastic Oscillator
- YMAB 15.12
- BWAY 58.73
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.